Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
Immunome presented detailed Phase 3 RINGSIDE data for varegacestat at ASCO, showing an 84% reduction in the risk of disease progression or death versus placebo (HR 0.16). The drug achieved a 56% objective response rate compared to 9% for placebo, with clinically significant pain reduction observed as early as week 4.
Key figures
- Drug Name
- varegacestat
- Phase Of Trial
- Phase 3
- Orr placebo
- 9%
- Orr varegacestat
- 56%
- Pfs hazard ratio
- 0.16
- Pfs risk reduction
- 84%
- Median exposure months
- 20.3
- Discontinuation rate ae
- 20%
- Tumor volume change week24
- -109.6
- Pain intensity change week12
- -2.24
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.